Back

Effects of mavacamten on the cellular response to beta adrenergic and frequency dependent stress in an HFpEF mouse model

29 August 2025 (16:15 - 17:00)
Organised by: Logo
Congress Presentation Part of: Heart failure: back to basics Heart Failure with Preserved Ejection Fraction (HFpEF) ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speakers

Photo
Mr Nesar Ahmad Aliyar

Berlin (Germany)

Photo
Mr Tobias Jeising

Berlin (Germany)

6 More presentations in this session

Presentation thumbnail
Flavin-containing monooxygenase 2 improves heart failure with preserved ejection fraction by promoting calcium-dependent nitric oxide synthesis
Professor X. Hu (Hangzhou, CN)
Abstract Slides Video
Presentation thumbnail
Targeting Cysteine 42 in PKGIa limits diastolic dysfunction in HFpEF
Doctor J. Su (London, GB)
Abstract Slides Video
Presentation thumbnail
Deletion of the E3 ubiquitin ligase MARCH1 promotes white adipose tissue beiging and attenuates diastolic dysfunction in a multi-hit mouse model of heart failure with preserved ejection fraction
Mr H. Yang (Changsha, CN)
Abstract Slides Video
Presentation thumbnail
From proteomics to precision: protein signatures as surrogate markers in phase II heart failure trials. A subanalysis from MYSTERY-HF
Doctor S. Braumann (Cologne, DE)
Abstract Slides Video
Presentation thumbnail
Humoral protein signature linked to circulating cell-free DNA in individuals with symptomatic heart failure
Ms E. Yapici (Mainz, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Heart failure: back to basics

The Event

Event poster

ESC Congress 2025

29 August 2025 16:15 CET
You may be interested in
thumbnail
Congress Presentation
Regressive sarcomere shortening response under rate-dependent stress in a murine model of HFpEF and chronic effect of CAMKII inhibition
thumbnail
Congress Presentation
Treatment of diastolic dysfunction by targeting beta-adrenergic receptors in vivo in a murine model of cardiometabolic HFpEF
thumbnail
Congress Session
Novel and targeted therapies: precision pharmacology in heart failure

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources